{"entity": "researcher", "timestamp": "2026-07-17T05:19:58.048Z", "family": "Li", "given": "Jiaxin", "initials": "J", "orcid": "0000-0002-5401-6855", "affiliations": ["Stem Cell Center, Lund University, Lund, Sweden. Jiaxin.Li@med.lu.se.", "Division of Neurosurgery, Department of Clinical Sciences, Lund University, Lund, Sweden. Jiaxin.Li@med.lu.se."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/8debd045d06f425bbc36426a8a2d9f8b.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/8debd045d06f425bbc36426a8a2d9f8b"}}, "publications": [{"entity": "publication", "iuid": "8d797864b1b0471fb92d281378e67c51", "links": {"self": {"href": "https://publications.scilifelab.se/publication/8d797864b1b0471fb92d281378e67c51.json"}, "display": {"href": "https://publications.scilifelab.se/publication/8d797864b1b0471fb92d281378e67c51"}}, "title": "Glioblastoma CD105+ cells define a SOX2- cancer stem cell-like subpopulation in the pre-invasive niche.", "authors": [{"family": "Li", "given": "Jiaxin", "initials": "J", "orcid": "0000-0002-5401-6855", "researcher": {"href": "https://publications.scilifelab.se/researcher/8debd045d06f425bbc36426a8a2d9f8b.json"}}, {"family": "Ek", "given": "Fredrik", "initials": "F"}, {"family": "Olsson", "given": "Roger", "initials": "R"}, {"family": "Belting", "given": "Mattias", "initials": "M"}, {"family": "Bengzon", "given": "Johan", "initials": "J"}], "type": "journal article", "published": "2022-08-29", "journal": {"title": "Acta Neuropathol Commun", "issn": "2051-5960", "issn-l": "2051-5960", "volume": "10", "issue": "1", "pages": "126"}, "abstract": "Glioblastoma (GBM) is the most common and most aggressive primary brain tumor in adults. Glioma stem like cells (GSC) represent the highest cellular hierarchy in GBM and have a determining role in tumor growth, recurrence and patient prognosis. However, a better definition of GSC subpopulations, especially at the surgical resection margin, is warranted for improved oncological treatment options. The present study interrogated cells expressing CD105 (CD105+) specifically within the tumor front and the pre-invasive niche as a potential GSC subpopulation. GBM primary cell lines were generated from patients (n = 18) and CD105+ cells were isolated and assessed for stem-like characteristics. In vitro, CD105+ cells proliferated and enriched in serum-containing medium but not in serum-free conditions. CD105+ cells were characterized by Nestin+, Vimentin+ and SOX2-, clearly distinguishing them from SOX2+ GCS. GBM CD105+ cells differentiated into osteocytes and adipocytes but not chondrocytes. Exome sequencing revealed that GBM CD105+ cells matched 83% of somatic mutations in the Cancer cell line encyclopedia, indicating a malignant phenotype and in vivo xenotransplantation assays verified their tumorigenic potential. Cytokine assays showed that immunosuppressive and protumorigenic cytokines such as IL6, IL8, CCL2, CXCL-1 were produced by CD105+ cells. Finally, screening for 88 clinical drugs revealed that GBM CD105+ cells are resistant to most chemotherapeutics except Doxorubicin, Idarubicin, Fludarabine and ABT-751. Our study provides a rationale for targeting tumoral CD105+ cells in order to reshape the tumor microenvironment and block GBM progression.", "doi": "10.1186/s40478-022-01422-8", "pmid": "36038950", "labels": {"Clinical Genomics Lund": "Service", "Clinical Genomics": "Service", "Chemical Biology Consortium Sweden": "Collaborative"}, "xrefs": [{"db": "pmc", "key": "PMC9426031"}, {"db": "pii", "key": "10.1186/s40478-022-01422-8"}], "notes": [], "created": "2022-10-10T10:56:58.805Z", "modified": "2025-10-17T13:04:27.845Z"}]}